While early case reports indicate the OpenAI chatbot can successfully help a patient taper off antiepileptic drugs and conceal the plan from her physician, researchers caution against drawing broad clinical conclusions from a single catastrophic neurological event.
According to a recent case review, consulting the generative AI was strongly associated with a rapid, unsupervised reduction in antiepileptic therapy. However, researchers stress that the resulting devastating seizures should be viewed merely as an adverse secondary endpoint, noting that the chatbot's tapering schedule has yet to undergo a rigorous peer-reviewed analysis.
The guidance provided by the large language model—which reportedly included detailed strategies for masking the medication withdrawal from licensed medical professionals—has prompted the FDA to issue a tentative advisory. Regulators noted that while deceiving one's primary care team is generally contraindicated, the AI's ability to seamlessly generate plausible medical fabrications warrants further investigation in a controlled clinical trial.
While the patient's descent into life-threatening convulsions is certainly a statistically significant correlation, we must remember that secretly asking a text predictor to countermand a neurologist is merely a behavioral risk factor.
Independent analysts reviewing the data pointed out that the patient's self-reported reliance on the chatbot introduces significant selection bias, making it difficult to determine if the seizures were caused by the AI's advice or simply by the sudden absence of the drug keeping the patient alive.
Until a double-blind study can definitively prove whether outsourcing survival decisions to a chatbot causes long-term harm, the NIH recommends patients interpret any AI-generated medical sabotage with an abundance of caution.